PhD Lenka Besse
Medizinische Onkologie und Hämatologie · Dept. I
Promising activity of nelfinavir-bortezomib-dexamethasone (NeVd) in proteasome inhibitor-refractory multiple myeloma
Driessen C, Pabst T, Hitz F, Hawle H, Rondeau S, Berset C, Besse A, Besse L, Ribi K, Samaras P, Mey U, Rüfer A, Mach N, Betticher D, Cantoni N, Novak U, Müller R, Zander T. Promising activity of nelfinavir-bortezomib-dexamethasone (NeVd) in proteasome inhibitor-refractory multiple myeloma. Blood 2018
20.09.2018Promising activity of nelfinavir-bortezomib-dexamethasone (NeVd) in proteasome inhibitor-refractory multiple myeloma
20.09.2018Blood 2018
Driessen Christoph, Pabst Thomas, Hitz Felicitas, Hawle Hanne, Rondeau Stephanie, Berset Catherine, Besse Andrej, Besse Lenka, Ribi Karin, Samaras Panagiotis, Mey Ulrich, Rüfer Axel, Mach Nicolas, Betticher Daniel, Cantoni Nathan, Novak Urban, Müller Rouven, Zander Thilo
The potential of CRISPR/Cas9 genome editing for the study and treatment of intervertebral disc pathologies.
Krupkova O, Cambria E, Besse L, Besse A, Bowles R, Wuertz-Kozak K. The potential of CRISPR/Cas9 genome editing for the study and treatment of intervertebral disc pathologies. JOR Spine 2018; 1:e1003.
15.03.2018The potential of CRISPR/Cas9 genome editing for the study and treatment of intervertebral disc pathologies.
15.03.2018JOR Spine 2018; 1:e1003
Krupkova Olga, Cambria Elena, Besse Lenka, Besse Andrej, Bowles Robert, Wuertz-Kozak Karin
Improving the efficacy of proteasome inhibitors in the treatment of renal cell carcinoma by combination with the human immunodeficiency virus (HIV)-protease inhibitors lopinavir or nelfinavir
Abt D, Driessen C, Engeler D, Schmid H, Slaby O, Vodinska M, Silzle T, Bader J, Kraus M, Sedlarikova L, Besse A, Besse L. Improving the efficacy of proteasome inhibitors in the treatment of renal cell carcinoma by combination with the human immunodeficiency virus (HIV)-protease inhibitors lopinavir or nelfinavir. BJU Int 2017
21.11.2017Improving the efficacy of proteasome inhibitors in the treatment of renal cell carcinoma by combination with the human immunodeficiency virus (HIV)-protease inhibitors lopinavir or nelfinavir
21.11.2017BJU Int 2017
Abt Dominik, Driessen Christoph, Engeler Daniel, Schmid Hans-Peter, Slaby Ondrej, Vodinska Martina, Silzle Tobias, Bader Juergen, Kraus Marianne, Sedlarikova Lenka, Besse Andrej, Besse Lenka
The first-in-class alkylating HDAC inhibitor EDO-S101 is highly synergistic with proteasome inhibition against multiple myeloma through activation of multiple pathways
Besse L, Kraus M, Besse A, Bader J, Silzle T, Mehrling T, Driessen C. The first-in-class alkylating HDAC inhibitor EDO-S101 is highly synergistic with proteasome inhibition against multiple myeloma through activation of multiple pathways. Blood Cancer J 2017; 7:e589.
28.07.2017The first-in-class alkylating HDAC inhibitor EDO-S101 is highly synergistic with proteasome inhibition against multiple myeloma through activation of multiple pathways
28.07.2017Blood Cancer J 2017; 7:e589
Besse Lenka, Kraus Marianne, Besse Andrej, Bader J, Silzle Tobias, Mehrling T, Driessen Christoph
Carfilzomib resistance due to ABCB1/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma
Besse A, Besse L, Overkleeft H, Bader J, Kraus M, Morgan G, Weinhold N, Rasche L, Stolze S, Driessen C. Carfilzomib resistance due to ABCB1/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma. Leukemia 2017; 32:391-401.
05.07.2017Carfilzomib resistance due to ABCB1/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma
05.07.2017Leukemia 2017; 32:391-401
Besse Andrej, Besse Lenka, Overkleeft H S, Bader J, Kraus Marianne, Morgan G J, Weinhold N, Rasche L, Stolze S C, Driessen Christoph
The novel β2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells.
Kraus J, Kraus M, Liu N, Besse L, Bader J, Geurink P, de Bruin G, Kisselev A, Overkleeft H, Driessen C. The novel β2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells. Cancer Chemother Pharmacol 2015; 76:383-96.
23.06.2015The novel β2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells.
23.06.2015Cancer Chemother Pharmacol 2015; 76:383-96
Kraus Johannes, Kraus Marianne, Liu Nora, Besse Lenka, Bader Jürgen, Geurink Paul P, de Bruin Gerjan, Kisselev Alexei F, Overkleeft Herman, Driessen Christoph